Haematology

Haematocrit targets: Is 45% still the right threshold for phlebotomy?

The 45% haematocrit threshold for phlebotomy in polycythaemia vera is a long-standing guideline, but its evidence base warrants re-examination for optimal patient outcomes.

Why molecular response in polycythemia vera remains an elusive endpoint

A network meta-analysis of polycythemia vera treatments was not feasible due to substantial heterogeneity in study designs and outcome definitions.

PNH: Beyond Eculizumab, How Proximal Inhibition Reshaped Treatment Goals

Paroxysmal nocturnal hemoglobinuria treatment has evolved from C5 inhibition to targeting earlier complement cascade components, aiming for more complete disease control.

When complement inhibitors fail: Recognizing breakthrough haemolysis

Breakthrough haemolysis on complement inhibitors requires prompt recognition and management to prevent severe complications in patients with complement-mediated diseases.

Oral factor B inhibition: a new path for PNH management?

Iptacopan, an oral factor B inhibitor, offers a novel approach to paroxysmal nocturnal hemoglobinuria (PNH) by targeting the alternative complement pathway.

Myelofibrosis: Why transplant timing dictates survival, not just symptoms

Early referral for allogeneic stem cell transplant in myelofibrosis patients with higher-risk disease is critical. Optimal timing balances disease progression against transplant-related mortality.

Choosing a JAK Inhibitor in Myelofibrosis: Beyond Ruxolitinib

Four JAK inhibitors manage myelofibrosis symptoms and splenomegaly, but patient-specific cytopenias dictate optimal agent selection.

Momelotinib and anaemia in myelofibrosis: a new calculus for treatment?

Momelotinib offers a distinct approach to myelofibrosis management, specifically addressing anaemia, a common and debilitating complication.

Gene therapy for thalassemia: Approval is one hurdle, access is the next

Gene therapy offers a new treatment option for thalassemia, but the complex logistics and high costs present significant barriers to patient access.